Literature DB >> 2185691

Multiple-dose pharmacokinetics of concurrent oral ciprofloxacin and rifampin therapy in elderly patients.

M H Chandler1, S M Toler, R P Rapp, R R Muder, J A Korvick.   

Abstract

The purpose of this clinical study was to investigate the influence of concomitant drug therapy with ciprofloxacin and rifampin on the individual pharmacokinetic profile of each agent in elderly patients. Twelve nursing home patients (age, 74 +/- 7 years), colonized with methicillin-resistant Staphylococcus aureus, were randomized to receive 14-day therapy with oral ciprofloxacin (750 mg every 12 h) (group A; n = 6) or ciprofloxacin (750 mg every 12 h) and oral rifampin (300 mg every 12 h) (group B; n = 6). Serial blood samples were obtained from 0 to 12 h following ciprofloxacin doses 1 and 13 and from 0 to 36 h after the last ciprofloxacin dose. No significant differences (P greater than 0.05) were found between or within groups in any pharmacokinetic parameter. The mean ciprofloxacin oral clearance values were 0.35 +/- 0.06, 0.41 +/- 0.15, and 0.38 +/- 0.11 liter/h per kg for doses 1, 13, and 28, respectively, in group A patients. The mean oral clearance values in group B patients for the respective doses were 0.53 +/- 0.36, 0.32 +/- 0.13, and 0.36 +/- 0.17 liter/h per kg. Likewise, no significant differences (P greater than 0.05) in rifampin pharmacokinetic parameters were found when compared with historical controls. These data suggest that ciprofloxacin and rifampin may be given concomitantly in standard clinical dosing regimens. The combination results in therapeutic levels of both drugs and appears to be safe for administration to elderly nursing home patients.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2185691      PMCID: PMC171612          DOI: 10.1128/AAC.34.3.442

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  30 in total

1.  Liquid-chromatographic determination of ciprofloxacin in serum and urine.

Authors:  D E Nix; J M De Vito; J J Schentag
Journal:  Clin Chem       Date:  1985-05       Impact factor: 8.327

2.  Impaired enzyme induction by rifampicin in the elderly.

Authors:  Y Twum-Barima; T Finnigan; A I Habash; R D Cape; S G Carruthers
Journal:  Br J Clin Pharmacol       Date:  1984-05       Impact factor: 4.335

3.  Quantitative assay of rifampicin and three of its metabolites in human plasma, urine and saliva by high-performance liquid chromatography.

Authors:  J B Lecaillon; N Febvre; J P Metayer; C Souppart
Journal:  J Chromatogr       Date:  1978-03-01

Review 4.  Metabolism and pharmacokinetics of the antibiotic rifampin.

Authors:  M T Kenny; B Strates
Journal:  Drug Metab Rev       Date:  1981       Impact factor: 4.518

Review 5.  Rifampin drug interactions.

Authors:  A M Baciewicz; T H Self
Journal:  Arch Intern Med       Date:  1984-08

6.  The emergence of methicillin-resistant Staphylococcus aureus infections in United States hospitals. Possible role of the house staff-patient transfer circuit.

Authors:  R W Haley; A W Hightower; R F Khabbaz; C Thornsberry; W J Martone; J R Allen; J M Hughes
Journal:  Ann Intern Med       Date:  1982-09       Impact factor: 25.391

7.  Reduced induction of drug metabolism in the elderly.

Authors:  S A Salem; P Rajjayabun; A M Shepherd; I H Stevenson
Journal:  Age Ageing       Date:  1978-05       Impact factor: 10.668

8.  Pharmacokinetic studies of rifampicin in the elderly.

Authors:  C Advenier; C Gobert; G Houin; D Bidet; S Richelet; J P Tillement
Journal:  Ther Drug Monit       Date:  1983       Impact factor: 3.681

Review 9.  Pharmacokinetics and metabolism of rifampin in humans.

Authors:  G Acocella
Journal:  Rev Infect Dis       Date:  1983 Jul-Aug

10.  The antimicrobial activity of rifampin: emphasis on the relation to phagocytes.

Authors:  G L Mandell
Journal:  Rev Infect Dis       Date:  1983 Jul-Aug
View more
  8 in total

Review 1.  Compositional dynamics of the human intestinal microbiota with aging: implications for health.

Authors:  B Lakshminarayanan; C Stanton; P W O'Toole; R P Ross
Journal:  J Nutr Health Aging       Date:  2014-11       Impact factor: 4.075

Review 2.  Pharmacokinetics of drugs used in critically ill adults.

Authors:  B M Power; A M Forbes; P V van Heerden; K F Ilett
Journal:  Clin Pharmacokinet       Date:  1998-01       Impact factor: 6.447

Review 3.  Ciprofloxacin. A review of its pharmacological profile and therapeutic use in the elderly.

Authors:  L R Wiseman; J A Balfour
Journal:  Drugs Aging       Date:  1994-02       Impact factor: 3.923

Review 4.  Quinolone disposition in the elderly. Practical implications.

Authors:  I Nilsson-Ehle; B Ljungberg
Journal:  Drugs Aging       Date:  1991 Jul-Aug       Impact factor: 3.923

Review 5.  Pharmacokinetic interactions with rifampicin : clinical relevance.

Authors:  Mikko Niemi; Janne T Backman; Martin F Fromm; Pertti J Neuvonen; Kari T Kivistö
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

6.  Crossover assessment of serum bactericidal activity and pharmacokinetics of ciprofloxacin alone and in combination in healthy elderly volunteers.

Authors:  M P Weinstein; R G Deeter; K A Swanson; J S Gross
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

7.  Influence of rifampin on fleroxacin pharmacokinetics.

Authors:  J Schrenzel; P Dayer; T Leemann; E Weidekamm; R Portmann; D P Lew
Journal:  Antimicrob Agents Chemother       Date:  1993-10       Impact factor: 5.191

Review 8.  A Physiologically-Based Pharmacokinetic Model to Describe Ciprofloxacin Pharmacokinetics Over the Entire Span of Life.

Authors:  Jan-Frederik Schlender; Donato Teutonico; Katrin Coboeken; Katrin Schnizler; Thomas Eissing; Stefan Willmann; Ulrich Jaehde; Heino Stass
Journal:  Clin Pharmacokinet       Date:  2018-12       Impact factor: 6.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.